Literature DB >> 33466910

Positive and Negative Affect Changes during Gender-Affirming Hormonal Treatment: Results from the European Network for the Investigation of Gender Incongruence (ENIGI).

Imke Matthys1, Justine Defreyne1, Els Elaut2, Alessandra Daphne Fisher3, Baudewijntje P C Kreukels4,5, Annemieke Staphorsius5,6, Martin Den Heijer5,6, Guy T'Sjoen1,2.   

Abstract

Improving transgender people's quality of life (QoL) is the most important goal of gender-affirming care. Prospective changes in affect can influence QoL. We aim to assess the impact of initiating gender-affirming hormonal treatment (HT) on affect. In the European Network for the Investigation of Gender Incongruence (ENIGI) study, we prospectively collected data of 873 participants (451 transwomen (TW) and 422 transmen (TM)). At baseline, psychological questionnaires including the Positive and Negative Affect Schedule (PANAS) were administered. The PANAS, levels of sex steroids and physical changes were registered at each follow-up visit during a 3-year follow-up period, starting at the initiation of hormonal therapy. Data were analyzed cross-sectionally and prospectively. Over the first three months, we observed a decline in positive affect (PA) in both TM and TW. Thereafter, PA reached a steady state in TW, whereas in TM there was also a second decline at 18 months. In both TM and TW there was no persisting difference comparing baseline to the 36-months results. Concerning negative affect (NA), we observed a decline during the first year in TM, which sustained during the second year and was not different anymore at 36 months compared to baseline. In TW though, we did not find any change of NA during the entire follow-up. Even if some of these results show significant differences, they should be considered with caution, since there was no control group and the absolute differences are small. No association between affect and the level of sex steroids was observed. Baseline QoL and psychological burden are related to affect independently from gender but are not necessarily good predictors of the evolution of one's affect during the gender-affirming process. Further research is necessary to investigate these preliminary results.

Entities:  

Keywords:  PANAS questionnaire; affect; antiandrogen therapy; estrogens; gender-affirming hormonal treatment; quality of life; testosterone; transgender

Year:  2021        PMID: 33466910      PMCID: PMC7829763          DOI: 10.3390/jcm10020296

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  22 in total

1.  Clinical assessment of body hair growth in women.

Authors:  D FERRIMAN; J D GALLWEY
Journal:  J Clin Endocrinol Metab       Date:  1961-11       Impact factor: 5.958

2.  Negative affect is unrelated to fluctuations in hormone levels across the menstrual cycle: Evidence from a multisite observational study across two successive cycles.

Authors:  Michael P Hengartner; Tillmann H C Kruger; Kirsten Geraedts; Enrico Tronci; Toni Mancini; Fabian Ille; Marcel Egli; Susanna Röblitz; Rainald Ehrig; Lanja Saleh; Katharina Spanaus; Cordula Schippert; Yuanyuan Zhang; Brigitte Leeners
Journal:  J Psychosom Res       Date:  2017-05-25       Impact factor: 3.006

3.  Mental Health and the Transgender Population.

Authors:  Tamar C Carmel; Laura Erickson-Schroth
Journal:  J Psychosoc Nurs Ment Health Serv       Date:  2016-12-01       Impact factor: 1.098

4.  Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence.

Authors:  Justine Defreyne; Els Elaut; Baudewijntje Kreukels; Alessandra Daphne Fisher; Giovanni Castellini; Annemieke Staphorsius; Martin Den Heijer; Gunter Heylens; Guy T'Sjoen
Journal:  J Sex Med       Date:  2020-01-31       Impact factor: 3.802

5.  Positive and negative affectivity and their relation to anxiety and depressive disorders.

Authors:  D Watson; L A Clark; G Carey
Journal:  J Abnorm Psychol       Date:  1988-08

6.  Psychiatric disorders in individuals diagnosed with gender dysphoria: A systematic review.

Authors:  Larissa Dias de Freitas; Gabriela Léda-Rêgo; Severino Bezerra-Filho; Ângela Miranda-Scippa
Journal:  Psychiatry Clin Neurosci       Date:  2019-11-25       Impact factor: 5.188

7.  Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment: A Multicenter Prospective Observational Study.

Authors:  Chantal M Wiepjes; Mariska C Vlot; Maartje Klaver; Nienke M Nota; Christel Jm de Blok; Renate T de Jongh; Paul Lips; Annemieke C Heijboer; Alessandra D Fisher; Thomas Schreiner; Guy T'Sjoen; Martin den Heijer
Journal:  J Bone Miner Res       Date:  2017-05-02       Impact factor: 6.741

8.  Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.

Authors:  Wylie C Hembree; Peggy Cohen-Kettenis; Henriette A Delemarre-van de Waal; Louis J Gooren; Walter J Meyer; Norman P Spack; Vin Tangpricha; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2009-06-09       Impact factor: 5.958

Review 9.  Healthcare costs and quality of life outcomes following gender affirming surgery in trans men: a review.

Authors:  Justine Defreyne; Joz Motmans; Guy T'sjoen
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2017-10-09       Impact factor: 2.217

10.  Positive and Negative Affect as Links Between Social Anxiety and Depression: Predicting Concurrent and Prospective Mood Symptoms in Unipolar and Bipolar Mood Disorders.

Authors:  Jonah N Cohen; M Taylor Dryman; Amanda S Morrison; Kirsten E Gilbert; Richard G Heimberg; June Gruber
Journal:  Behav Ther       Date:  2017-07-16
View more
  1 in total

Review 1.  The ENIGI (European Network for the Investigation of Gender Incongruence) Study: Overview of Acquired Endocrine Knowledge and Future Perspectives.

Authors:  Carlotta Cocchetti; Alessia Romani; Sarah Collet; Yona Greenman; Thomas Schreiner; Chantal Wiepjes; Martin den Heijer; Guy T'Sjoen; Alessandra Daphne Fisher
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.